EVALUATION OF CONCOMITANT CORTICOSTEROID AND VEDOLIZUMAB USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) IN REAL-LIFE CLINICAL PRACTICE
Author(s)
Ylisaukko-Oja T1, Torvinen S1, Aaltonen J1, Vihervaara V2, Eberl A3, Nuutinen H4, Blomster T5, Jussila A6, Pajala M7, Jokelainen J8, Herrala S8, Tamminen K2, Sipponen T3
1Takeda, Helsinki, Finland, 2Takeda Oy, Helsinki, Finland, 3University Hospital and University of Helsinki, Helsinki, Finland, 4Turku University Hospital, Turku, Finland, 5Oulu University Central Hospital, Oulu, Finland, 6Tampere University Hospital, Tampere, Finland, 7Kuopio University Hospital, Kuopio, Finland, 8MedEngine, Helsinki, Finland
OBJECTIVES: Corticosteroids (CS) are often used concominantly with biologics in treatment of inflammatory bowel disease (IBD). However, their side-effect profile causes significant clinical and economic burden in long-term treatment. In this study, we investigated the impact of concomitant CS use on vedolizumab treatment persistence in patients with Crohn’s disease (CD) and ulcerative colitis (UC). METHODS: This was a nationwide (Finland), retrospective, non-interventional, multi-center chart review. From 27 centers, we included adult (≥ 18 years of age) IBD patients who received at least one vedolizumab infusion since 2014. Data were collected from medical charts in a standardized case report form. The key data collection points were at baseline, week 14 and month 6 of vedolizumab treatment. RESULTS: CONCLUSIONS: Vedolizumab treatment persistence was lower in CS users than in non-users in both CD and UC. The majority of patients on CS at baseline who persisted on vedolizumab were steroid-free by 6 months, potentially relieving the burden of CS-induced side-effects for both patients and society.
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PGI6
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Gastrointestinal Disorders